Related Experiment Video
Updated: Sep 19, 2025
05:31
Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
951
L-Citrulline Improves IGF-1 Signaling Pathway in Preeclampsia via Polyamines.
Andy W C Man1, Joscha Steetskamp2, Josche van der Ven2
1Department of Pharmacology (A.W.C.M., G.R., N.X., H.L.), Cardiology I, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
Hypertension (Dallas, Tex. : 1979)
|June 2, 2025
Summary
L-citrulline supplementation may treat preeclampsia by enhancing insulin-like growth factor 1 (IGF-1) signaling, partly through polyamine production. This offers a potential therapeutic strategy for this severe pregnancy complication.
Area of Science:
- Obstetrics and Gynecology
- Molecular Medicine
- Nutritional Science
Background:
- Preeclampsia is a severe pregnancy complication lacking effective pharmacological treatments.
- Previous studies showed L-citrulline improves preeclampsia in a rat model.
- This study investigates the molecular mechanisms of L-citrulline's effects.
Purpose of the Study:
- To elucidate the molecular mechanisms by which L-citrulline supplementation impacts preeclampsia.
- To investigate the role of IGF-1 signaling and polyamine metabolism in preeclampsia.
- To explore L-citrulline as a potential therapeutic agent for preeclampsia.
Main Methods:
- Treatment of pregnant Dahl salt-sensitive rats with L-citrulline.
- Recruitment of preeclampsia patients for placental and serum sample collection.
- Analysis of placental gene expression (IGF-1, ZEB1, miR-486-5p, miR-210) and serum polyamine levels.
Main Results:
- Preeclamptic placentas showed reduced IGF-1, ZEB1, and increased miR-486-5p, miR-210.
- L-citrulline treatment in rats normalized these placental markers and maintained serum polyamine levels.
- L-citrulline and polyamines improved IGF-1 expression in cultured cells, with effects partly dependent on IGF-1.
Conclusions:
- L-citrulline supplementation improves IGF-1 signaling in preeclampsia, partly via polyamine production.
- Maternal L-citrulline or polyamine supplementation may be a safe and effective therapeutic strategy for preeclampsia.
Related Concept Videos
01:33Hormonal Regulation
33.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.7K
01:24Glucagon-like Receptor Agonists
438
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
438
01:28Nitric Oxide Signaling Pathway
5.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
260
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
260